Akers Awarded CFDA Approval for Heparin-Reaction Diagnostic

Akers Biosciences of the US received CFDA approval of its diagnostic test for allergic reactions to heparin, the blood thinner. Akers' PIFA Heparin/PF4 Rapid Assay (and the whole blood PIFA PLUSS PF4 version) test for PF4 antibodies, which are associated with heparin-induced thrombocytopenia (HIT). The Akers diagnostic is the first test for the condition approved in China. NovoTek of Beijing will be in charge of China distribution. More details.... Stock Symbols: (NSDQ: AKER; AIM:AKR.L) Share this with colleagues: // //